help button home button Am J Pathol International Conference on Pathology of Chest Diseases
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Originally published online as doi:10.2353/ajpath.2008.070395 on December 21, 2007

Published online before print December 21, 2007
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
ajpath.2008.070395v1
172/1/256    most recent
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lawrie, A.
Right arrow Articles by Newman, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lawrie, A.
Right arrow Articles by Newman, C.
(American Journal of Pathology. 2008;172:256-264.)
© 2008 American Society for Investigative Pathology
DOI: 10.2353/ajpath.2008.070395

Evidence of a Role for Osteoprotegerin in the Pathogenesis of Pulmonary Arterial Hypertension

Allan Lawrie*, Elizabeth Waterman{dagger}, Mark Southwood{ddagger}, David Evans*, Jay Suntharalingam{ddagger}, Sheila Francis*, David Crossman*, Peter Croucher§, Nicholas Morrell{ddagger} and Christopher Newman*

From the Cardiovascular Research Unit,*Academic Unit of Urology,{dagger}School of Medicine and Biomedical Sciences, University of Sheffield, Sheffield; the Department of Medicine,{ddagger}University of Cambridge School of Clinical Medicine, Addenbrooke’s and Papworth Hospitals, Cambridge; and the Academic Unit of Bone Biology,§School of Medicine and Biomedical Sciences, University of Sheffield, Sheffield, United Kingdom

Pulmonary artery smooth muscle cell (PA-SMC) migration and proliferation are key processes in the pathogenesis of pulmonary arterial hypertension (PAH). Recent information suggests that abnormalities in the bone morphogenetic protein (BMP) receptor 2 (BMP-R2) signaling pathway are important in PAH pathogenesis. It remains unclear whether and how this pathway interacts with, for example, serotonin (5-HT) and inflammation to trigger and/or sustain the development of PAH. The secreted glycoprotein osteoprotegerin (OPG) is emerging as an important regulatory molecule in vascular biology and is modulated by BMPs, 5-HT, and interleukin-1 in other cell types. However, whether OPG is expressed by PA-SMCs within PAH lesions and plays a role in PAH is unknown. Immunohistochemistry of human PAH lesions demonstrated increased OPG expression, and OPG was significantly increased in idiopathic PAH patient serum. Recombinant OPG stimulated proliferation and migration of PA-SMCs in vitro, and BMP-R2 RNA interference increased OPG secretion. Additionally, both 5-HT and interleukin-1 also increased OPG secretion. These data are the first to demonstrate that OPG is increased in PAH and that it can regulate PA-SMC proliferation and migration. OPG may provide a common link between the different pathways associated with the disease, potentially playing an important role in the pathogenesis of PAH.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by the American Society for Investigative Pathology.